---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-085860"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T16:53:07.570268+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alkermes Q2 2024 GAAP EPS $0.55; proprietary sales up 16% YoY; reiterates guidance

## Summary
- Total revenues $399.1M, GAAP net income from continuing ops $94.7M; non-GAAP net income $123.4M.
- Proprietary net sales $269.3M (+16% YoY); LYBALVI $71.4M (+52%), VIVITROL $111.9M (+10%).
- Cash & investments $962.5M; repurchased 3.5M shares for $84.7M in Q2; $315.3M remaining.
- Positive phase 1b ALKS 2680 data in narcolepsy; initiated Vibrance-1 phase 2 for NT1.
- Reiterated 2024 financial expectations; sold Athlone facility to Novo Nordisk for ~$91M.

## SEC filing metadata
- accession: 0000950170-24-085860
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017024085860/0000950170-24-085860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017024085860/alks-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-085860
- JSON: https://secwatch.observer/filing/0000950170-24-085860.json
- Plain text: https://secwatch.observer/filing/0000950170-24-085860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.